| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/27/2000 | CA2361168A1 Steroid sulfatase inhibitors and methods for making and using the same |
| 07/27/2000 | CA2361124A1 Vaccine-mediated treatment of neurological disorders |
| 07/27/2000 | CA2361123A1 Methods for identifying, treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| 07/27/2000 | CA2361122A1 Methods and devices for delivery of agents to breast milk ducts |
| 07/27/2000 | CA2361064A1 Boron steroid mimics and pharmaceutical compositions |
| 07/27/2000 | CA2361059A1 Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use |
| 07/27/2000 | CA2360908A1 Bis-terpyridine-platinum(ii) complexes |
| 07/27/2000 | CA2360787A1 Phosphinic pseudopeptides inhibitors of matrix metalloproteases |
| 07/27/2000 | CA2360609A1 Basb055 polynucleotide and polypeptide from neisseria meningitidis. uses thereof |
| 07/27/2000 | CA2360066A1 A pharmaceutical composition containing a compound having a phenolic hydroxyl group with coloring change being controlled |
| 07/27/2000 | CA2360062A1 Baff, inhibitors thereof and their use in the modulation of b-cell response |
| 07/27/2000 | CA2360038A1 Methods for reducing mortality rates in poultry |
| 07/27/2000 | CA2359983A1 Phenylsulphonyl derivatives as 5-ht receptor ligands |
| 07/27/2000 | CA2359709A1 Multiparticulate bisoprolol formulation |
| 07/27/2000 | CA2359680A1 Kinase inhibitors |
| 07/27/2000 | CA2359641A1 Chewing gum with dental health benefits employing calcium lactate |
| 07/27/2000 | CA2359627A1 Multi-purpose acid compositions comprising three gras acids |
| 07/27/2000 | CA2359587A1 Compact dosage unit for buccal administration of steroidal active agent |
| 07/27/2000 | CA2359572A1 Substituted 1-(piperidin-4-yl)-3-(aryl)-isothioureas, their preparation and therapeutic use |
| 07/27/2000 | CA2359564A1 Method to aid smoking cessation |
| 07/27/2000 | CA2359482A1 Organoprotective solutions |
| 07/27/2000 | CA2359145A1 Exocytosis pathway proteins and methods of use |
| 07/27/2000 | CA2359114A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/27/2000 | CA2359113A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/27/2000 | CA2359112A1 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/27/2000 | CA2359107A1 New benzimidazole compounds for use as active therapeutic substances, process for the preparation of these compoudns and pharmaceutical compositions comprising them |
| 07/27/2000 | CA2359105A1 New morpholinobenzamide salts |
| 07/27/2000 | CA2359103A1 Substituted 1-(pieridin-4-yl)-3-(aryl) isothioureas their preparation and therapeutic application |
| 07/27/2000 | CA2358971A1 Identifying, monitoring, and treating women for breast precancer or cancer |
| 07/27/2000 | CA2358899A1 Polypeptide |
| 07/27/2000 | CA2358584A1 Method of enhancing needleless transdermal powdered drug delivery |
| 07/27/2000 | CA2358524A1 Compositions and methods for mucosal delivery |
| 07/27/2000 | CA2357781A1 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/27/2000 | CA2356681A1 Metalloproteinase-disintegrin family members: svph dnas and polypeptides |
| 07/27/2000 | CA2356349A1 Novel angiogenesis inhibitors |
| 07/27/2000 | CA2355738A1 3,6-disubstituted penam sulfone derivatives as antibacterials |
| 07/27/2000 | CA2353903A1 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases |
| 07/26/2000 | EP1022338A2 Viral vaccines |
| 07/26/2000 | EP1022278A1 Tetracyclical derivatives from pyrimidine |
| 07/26/2000 | EP1022277A1 New taxane derivatives |
| 07/26/2000 | EP1022274A1 Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use |
| 07/26/2000 | EP1022272A1 Substituted fused heterocyclic compounds |
| 07/26/2000 | EP1022030A1 Plasminogen activator inhibitor 1 production regulatory agents |
| 07/26/2000 | EP1022029A1 Nootropic agent |
| 07/26/2000 | EP1022028A1 Sustained-release oral preparation |
| 07/26/2000 | EP1022026A2 Pharmaceutical compositions for treating nitrate-induced tolerance |
| 07/26/2000 | EP1022025A2 Method and compositions for treating emesis nausea and other disorders using optically pure R(+) ondansetron |
| 07/26/2000 | EP1022024A2 Anticholestatic activity of luteolin, apigenin and naringenin |
| 07/26/2000 | EP1022023A1 Composition suitable as food integrator and for the treatment of intestinal disorders and alterations of the bacterial flora |
| 07/26/2000 | EP1022022A1 Composition for inhibiting increase of blood sugar level or lowering blood sugar level |
| 07/26/2000 | EP1021564A1 Process for detecting, extracting or removing human or mammalian cells with a disturbed cellular cycle regulation or unlimited proliferation or tumour-forming ability |
| 07/26/2000 | EP1021549A2 SENSE mRNA THERAPY |
| 07/26/2000 | EP1021537A1 T cell receptor-associated molecules (trams) and methods of use therefor |
| 07/26/2000 | EP1021536A2 Mammalian genes involved in viral infection and tumor suppression |
| 07/26/2000 | EP1021533A1 Nucleic acids coding for proteins capable of interacting with presenilins |
| 07/26/2000 | EP1021456A1 Macrocyclic 13-membered ring derivatives of erythromycins a and b |
| 07/26/2000 | EP1021448A1 TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS |
| 07/26/2000 | EP1021447A1 Pyrrolopyrazolopyrimidine compound and medicine comprising the same |
| 07/26/2000 | EP1021446A1 Single pot process for producing (z)-azabicyclo oxime ethers |
| 07/26/2000 | EP1021445A1 Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment |
| 07/26/2000 | EP1021444A1 3-CARBOXAMIDE DERIVATIVES OF 5H-PYRROLO[2,1-c][1,4]-BENZODIAZEPINES |
| 07/26/2000 | EP1021443A1 Hemoregulatory compounds |
| 07/26/2000 | EP1021442A1 8-azabicyclo 3.2.1] octane-3-methanamine derivatives as ligands of d2 and d3 dopamine and 5ht1a and 5ht2 serotonin receptors |
| 07/26/2000 | EP1021440A2 Antipsychotic substituted piperidine derivatives |
| 07/26/2000 | EP1021439A1 Crystalline antifungal polymorph |
| 07/26/2000 | EP1021438A1 Trioxane dimer compounds having antiproliferative and antitumor activities |
| 07/26/2000 | EP1021437A1 Arylsulfonylimidazolone derivatives as an antitumor agent |
| 07/26/2000 | EP1021436A1 ETHYL 4-(8-CHLORO-5, 6-DIHYDRO-11H- BENZO 5,6]CYCLOHEPTA 1,2-b]PYRIDIN -11-YLIDENE)-1- PIPERIDENE CARBOXYLATE POLYMORPH |
| 07/26/2000 | EP1021435A1 Solid phase and combinatorial synthesis of substituted thiophenes and of arrays of substituted thiophenes |
| 07/26/2000 | EP1021434A2 Pharmacologically active compounds and use |
| 07/26/2000 | EP1021432A1 Halogen substituted tetracyclic tetrahydrofuran derivatives |
| 07/26/2000 | EP1021430A1 Furan nitrone compounds |
| 07/26/2000 | EP1021429A1 Aryl furan derivatives as pde iv inhibitors |
| 07/26/2000 | EP1021425A1 N-aminoalkyl-2-anthraquinonecarboxamides; dopamine receptor subtype specific ligands |
| 07/26/2000 | EP1021423A1 MACROCYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF$g(a) SECRETION |
| 07/26/2000 | EP1021418A1 Substituted 2,3-benzodiazepin-4-ones and the use thereof |
| 07/26/2000 | EP1021415A1 Tricyclic aminoalkylcarboxamides; novel dopamine d 3? receptor subtype specific ligands |
| 07/26/2000 | EP1021413A1 The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 07/26/2000 | EP1021411A1 Benzamide derivatives as thrombin inhibitors |
| 07/26/2000 | EP1021410A1 Prostaglandin agonists and their use to treat bone disorders |
| 07/26/2000 | EP1021407A1 Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
| 07/26/2000 | EP1021406A1 Novel anandamide amidase inhibitors as analgesic agents |
| 07/26/2000 | EP1021405A1 Azetidinone derivatives for the treatment of hcmv infections |
| 07/26/2000 | EP1021404A1 Azetidinone derivatives for the treatment of hcmv infections |
| 07/26/2000 | EP1021402A1 Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists |
| 07/26/2000 | EP1021401A1 Calcitriol derivatives and their uses |
| 07/26/2000 | EP1021397A1 Benzanthrone compounds and antiviral uses thereof |
| 07/26/2000 | EP1021201A1 Use of growth differenciation factor-9 (gdf-9) as a contraceptive |
| 07/26/2000 | EP1021199A1 PEPTIDE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS |
| 07/26/2000 | EP1021198A1 Flavonolignan preparations, especially silymarin preparations |
| 07/26/2000 | EP1021195A1 Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine |
| 07/26/2000 | EP1021194A1 New improved formulation for treatment of osteoporosis |
| 07/26/2000 | EP1021193A1 THERAPEUTICALLY EFFECTIVE 1$g(a), 25-DIHYDROXYVITAMIN D 3? ANALOGS |
| 07/26/2000 | EP1021192A1 Dexamethasone gel |
| 07/26/2000 | EP1021191A2 Tightening and/or reducing the size of body parts containing fat cells |
| 07/26/2000 | EP1021190A1 Novel amide derivatives |
| 07/26/2000 | EP1021189A1 Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation |
| 07/26/2000 | EP1021188A1 Inhibitors of prenyl-protein transferase |
| 07/26/2000 | EP1021187A1 Methods and compositions for protecting against cardiac ischemia by administering adenosine a 2a? receptor antagonists |
| 07/26/2000 | EP1021186A1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha |